FilingReader Intelligence
Shanghai Pharma's B019 gains lupus trial approval
August 4, 2025 at 07:05 AM UTC•By FilingReader AI
Shanghai Pharmaceuticals Holding announced its B019 injection, a dual-targeting CAR-T cell therapy, received approval for clinical trials in treating refractory systemic lupus erythematosus.
This marks the third indication for B019, which also has approvals for acute B-lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
SSE:601607•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Pharmaceuticals Holding publishes news
Free account required • Unsubscribe anytime